🇺🇸 NPH human insulin in United States

40 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypoglycaemia — 7 reports (17.5%)
  2. Blood Glucose Decreased — 5 reports (12.5%)
  3. Blood Glucose Increased — 5 reports (12.5%)
  4. Cerebrovascular Accident — 4 reports (10%)
  5. Diabetes Mellitus Inadequate Control — 4 reports (10%)
  6. Pharmaceutical Product Complaint — 4 reports (10%)
  7. Arteriosclerosis — 3 reports (7.5%)
  8. Hyperglycaemia — 3 reports (7.5%)
  9. Pleural Effusion — 3 reports (7.5%)
  10. Alanine Aminotransferase Increased — 2 reports (5%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is NPH human insulin approved in United States?

NPH human insulin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for NPH human insulin in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.